CAS: 859212-16-1; (S)-N-(3-([4,5'-Bipyrimidin]-2-Ylamino)-4-Methylphenyl)-4-((3-(Dimethylamino)Pyrrolidin-1-yl)Methyl)-3-(Trifluoromethyl)Benzamide

上下游产品

4-(Bromomethyl)-3-Trifluoromethyl-N-{4-Methyl-3-[4-(5-Pyrimidinyl)Pyrimidin-2-Ylamino]Phenyl}Benzamide 859213-40-4

📜4-甲基-3-(三氟甲基)苯甲酸置于sodium Bromate,草酰氯,Potassium Carbonate,Sodium Hydrogensulfite,N,N-二甲基甲酰胺体系中,用 1,4-二氧六环,二氯甲烷,乙酸乙酯,N,N-二甲基甲酰胺 作为反应溶剂,化学反应生成 巴氟替尼
参考文献:Design And Synthesis Of 3-Substituted Benzamide Derivatives As Bcr-Abl Kinase Inhibitors
标题:Design And Synthesis Of 3-Substituted Benzamide Derivatives As Bcr-Abl Kinase Inhibitors
摘要:A Series Of 3-Substituted Benzamide Derivatives Structurally Related To Sti-571 (Imatinib Mesylate),A Bcr-Abl Tyrosine Kinase Inhibitor Used To Treat Chronic Myeloid Leukemia (Cml),Was Prepared And Evaluated For Antiproliferative Activity Against The Bcr-Abl-Positive Leukemia Cell Line K562. About Ten 3-Halogenated And 3-Trifluoromethylated Benzamide Derivatives Were Identified As Highly Potent Bcr-Abl Kinase Inhibitors. One Of These,Ns-187 (9B),Is A Promising New Candidate Bcr-Abl Inhibitor For The Therapy Of Sti-571-Resistant Chronic Myeloid Leukemia. (C) 2005 Elsevier Ltd. All Rights Reserved.
DOI:10.1016/j.Bmcl.2005.11.042

专利信息

专利号:US-12240835-B2
优先权日:2018-09-18
标题:Substituted benzamides as intermediates in the synthesis of inhibitors of tyrosine kinase enzymatic activity
发明人：ROMERO F ANTHONY; KIRSCHBERG THORSTEN A; HALCOMB RANDALL; XU YINGZI
权利人:TERNS PHARMACEUTICALS INC
摘要:Provided herein are compounds, preferably compounds inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, compositions thereof, and methods of their preparation, and methods of inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, and methods for treating diseases wherein modulation of BCR-ABL1 activity prevents, inhibits, or ameliorates the pathology and/or symptomology of the disease. Intermediates such as compounds of Formula (S23), which are useful in the synthesis of compounds inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, are also provided.

专利号:US-11759496-B2
优先权日:2016-05-10
标题:Compounds and pharmaceutical use thereof in the treatment of cancer
发明人：SUSIN SANTOS A; KAROYAN PHILIPPE; MERLE-BERAL HÉLÈNE
权利人:KAROYAN PHILIPPE
摘要:The present invention relates to a compound or a pharmaceutical salt thereof comprising a hexapeptide sequence of formula (I), its method of synthesis and its use in anticancer therapy. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier.

专利号:WO-2024117980-A1
优先权日:2022-12-02
标题 :Compounds for modulating src family kinases and uses thereof
发明人：KUMAR ALAN PREM; SETHI GAUTAM; LEE E HUI CLARISSA; - BASAPPA; RANGAPPA KANCHUGARAKOPPAL S; MOHAN CHAKRABHAVI DHANANJAYA
权利人:NAT UNIV SINGAPORE; UNIV OF MYSORE
摘要:The present invention relates to chalcone (CHL) compounds, their synthesis, and applications in modulating the activity of Src Family Kinases (SFKs), specifically Lyn kinase, and methods of use in treating various diseases and conditions associated with aberrant activity of Src Family Kinases.